Andy Lim, MBA FACEM GAICD
European Stroke Organisation Conference
May 4-6, 2022
Sadly, we reached the final day of the 8th European Stroke Organisation Conference in Lyon, France.
My time was spent in the Gratte-Ciel 1-3 room, where we presented the outcomes of eight new studies. Here are eight learning points from our session.
Thomas Meinel (Switzerland)
- Three-month futile acute revascularization can be predicted by a multivariable model including clinical, laboratory, imaging, and time-to-treatment features.
Wouter Sluis (Netherlands)
- Stroke severity after EVT, hyperglycemia at baseline, and pre-stroke functional dependency predict 90d mortality after endovascular stroke treatment, with pneumonia being the most common cause of death.
Andy Lim (Australia)
- A meta-analysis of randomized trials and observational studies revealed that ninety-day stroke recurrence rate in minor stroke is 8.4%. This rate is declining by 0.69% per year.
Hend Abdelhamid (US)
- Age, baseline NIHSS, number of passes, history of prior stroke, long LWK-puncture time, low hematocrit value, CAD, and non-smoking were independent predictors of poor outcome in LVOs with small final infarct volume.
Ann-Cathrin Probst (Germany)
- Relevant comorbidity burden and polypharmacy are common after thrombectomy for acute ischemic stroke, with comorbidity burden being a risk factor for worse functional outcome.
Amit Mistri (UK)
- Retinal ischemic events lasting >24hrs have higher mortality and lower survival rate in a cohort presenting to TIA clinic when compared to those lasting <24hrs.
Nikita Chhabra (US)
- No significant difference in favorable discharge (mRS ≤ 3) between EVT and medical management in patients with acute basilar artery occlusion in a retrospective cohort study.
Lynda Lisabeth (US)
- The majority of those with stroke have clinically significant sleep disordered breathing and three-quarters experience stable high or worsening SDB severity in the year following stroke. Predicting which patients experience stable or worsening SDB may allow for targeted SDB screening and ongoing treatment to improve outcomes.